获批上市-话题@MedSci

#获批上市#

99篇内容 | 2623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1632627, encodeId=2fe2163262edd, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=Nutrition and Metabolic Insights：“解酒神药”获批上市，1小时内分解70%酒精，100%天然成分，预防宿醉, objectType=article, longId=732152, objectId=0324e3215202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0324e3215202, replyNumber=0, likeNumber=119, createdTime=2023-06-20, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0324e3215202, moduleTitle=Nutrition and Metabolic Insights：“解酒神药”获批上市，1小时内分解70%酒精，100%天然成分，预防宿醉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0324e3215202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632626, encodeId=32151632626af, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市, objectType=article, longId=727904, objectId=c91be2790430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c91be2790430, replyNumber=0, likeNumber=128, createdTime=2023-02-25, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c91be2790430, moduleTitle=喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c91be2790430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632625, encodeId=c2491632625c2, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市, objectType=article, longId=725779, objectId=c4c1e2577962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4c1e2577962, replyNumber=0, likeNumber=125, createdTime=2022-11-07, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4c1e2577962, moduleTitle=辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4c1e2577962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632628, encodeId=5ed916326281c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=Nutr Metab Insights：“解酒神药”获批上市，1小时分解70%酒精, objectType=article, longId=732640, objectId=9db5e3264040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db5e3264040, replyNumber=0, likeNumber=116, createdTime=2023-01-22, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db5e3264040, moduleTitle=Nutr Metab Insights：“解酒神药”获批上市，1小时分解70%酒精, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db5e3264040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632622, encodeId=ebe5163262294, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=新型抗生素！国家1类新药纽再乐®获批上市，应对多重耐药细菌, objectType=article, longId=291885, objectId=36dc2918856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36dc2918856a, replyNumber=0, likeNumber=124, createdTime=2022-07-17, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36dc2918856a, moduleTitle=新型抗生素！国家1类新药纽再乐®获批上市，应对多重耐药细菌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36dc2918856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632618, encodeId=a184163261886, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市, objectType=article, longId=215308, objectId=e71d21530816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71d21530816, replyNumber=0, likeNumber=127, createdTime=2021-08-06, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71d21530816, moduleTitle=济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e71d21530816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632624, encodeId=2b3b1632624ec, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=千呼万唤始出来！盐酸决奈达隆终于获批上市，房颤治疗迈入新时代, objectType=article, longId=302264, objectId=55393022649d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55393022649d, replyNumber=0, likeNumber=120, createdTime=2022-11-07, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55393022649d, moduleTitle=千呼万唤始出来！盐酸决奈达隆终于获批上市，房颤治疗迈入新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55393022649d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632621, encodeId=34661632621e1, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=2021年12月10日简报：多数奥密克戎变异株感染病例症状轻微，中国新冠特效药中和抗体获批上市, objectType=article, longId=221823, objectId=ab2d2218234a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2d2218234a, replyNumber=0, likeNumber=101, createdTime=2022-05-20, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2d2218234a, moduleTitle=2021年12月10日简报：多数奥密克戎变异株感染病例症状轻微，中国新冠特效药中和抗体获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2d2218234a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632611, encodeId=7d2316326110d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=国家药监局：92个医疗器械产品获批上市, objectType=article, longId=208908, objectId=040020890803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040020890803, replyNumber=0, likeNumber=117, createdTime=2022-02-04, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040020890803, moduleTitle=国家药监局：92个医疗器械产品获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=040020890803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632606, encodeId=2b231632606aa, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=102, createdTime=2021-05-03, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632623, encodeId=a6661632623ac, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！, objectType=article, longId=292245, objectId=244229224531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=244229224531, replyNumber=0, likeNumber=110, createdTime=2022-06-06, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=244229224531, moduleTitle=直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=244229224531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632620, encodeId=7c7f16326209c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, objectType=article, longId=221354, objectId=a16422135482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16422135482, replyNumber=0, likeNumber=102, createdTime=2022-06-17, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16422135482, moduleTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16422135482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632603, encodeId=cc7a1632603ff, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=特大喜讯！中国新冠病毒疫苗获批上市，全民免费！, objectType=article, longId=205095, objectId=ec1320509530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec1320509530, replyNumber=0, likeNumber=95, createdTime=2021-01-22, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec1320509530, moduleTitle=特大喜讯！中国新冠病毒疫苗获批上市，全民免费！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec1320509530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632613, encodeId=656416326131b, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=500多万癫痫儿童用药有了新选择，优时比维派特®口服溶液获批上市, objectType=article, longId=209179, objectId=e73f2091e97f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e73f2091e97f, replyNumber=0, likeNumber=98, createdTime=2022-01-12, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e73f2091e97f, moduleTitle=500多万癫痫儿童用药有了新选择，优时比维派特®口服溶液获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e73f2091e97f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632617, encodeId=a195163261e9f, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！, objectType=article, longId=213096, objectId=9fe22130966a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fe22130966a, replyNumber=0, likeNumber=110, createdTime=2021-06-29, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fe22130966a, moduleTitle=中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fe22130966a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632619, encodeId=b3ee16326193c, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=韩国GC绿十字公司血友病药物绿茵芷获批上市, objectType=article, longId=215581, objectId=f9c22155815f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c22155815f, replyNumber=0, likeNumber=111, createdTime=2022-07-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c22155815f, moduleTitle=韩国GC绿十字公司血友病药物绿茵芷获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c22155815f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632604, encodeId=08ac16326048a, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=武田高血压新药「美阿沙坦钾片」在中国获批上市, objectType=article, longId=206131, objectId=1540206131de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1540206131de, replyNumber=0, likeNumber=114, createdTime=2021-10-06, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1540206131de, moduleTitle=武田高血压新药「美阿沙坦钾片」在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1540206131de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632610, encodeId=c0271632610e7, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=第二个国产三代EGFR-TKI获批上市, objectType=article, longId=208092, objectId=47f52080927e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f52080927e, replyNumber=0, likeNumber=119, createdTime=2022-01-28, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f52080927e, moduleTitle=第二个国产三代EGFR-TKI获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f52080927e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632607, encodeId=3faa163260e54, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=两款国产疫苗同时获批上市，老年人群将全面覆盖, objectType=article, longId=207650, objectId=22c920e650aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22c920e650aa, replyNumber=0, likeNumber=98, createdTime=2021-12-26, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22c920e650aa, moduleTitle=两款国产疫苗同时获批上市，老年人群将全面覆盖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22c920e650aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632612, encodeId=912e163261203, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, objectTitle=全球**抗过敏型隐形眼镜正式获批上市, objectType=article, longId=209053, objectId=098e20905359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=098e20905359, replyNumber=0, likeNumber=102, createdTime=2022-01-15, rootId=0, userName=weiz, userId=820f21933891, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=098e20905359, moduleTitle=全球**抗过敏型隐形眼镜正式获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=098e20905359)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

获批上市

2020-05-29

weiz (审核中...)

前往app查看评论内容

#获批上市#

Nutrition and Metabolic Insights：“解酒神药”获批上市，1小时内分解70%酒精，100%天然成分，预防宿醉

2023-06-20

weiz (审核中...)

前往app查看评论内容

#获批上市#

喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市

2023-02-25

weiz (审核中...)

前往app查看评论内容

#获批上市#

辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市

2022-11-07

weiz (审核中...)

前往app查看评论内容

#获批上市#

Nutr Metab Insights：“解酒神药”获批上市，1小时分解70%酒精

2023-01-22

爆笑小医 (审核中...)

前往app查看评论内容

#获批上市#

新型抗生素！国家1类新药纽再乐®获批上市，应对多重耐药细菌

2022-07-17

weiz (审核中...)

前往app查看评论内容

#获批上市#

济民可信成功引进“索立德吉” 国内基底细胞癌药物获批上市

2021-08-06

weiz (审核中...)

前往app查看评论内容

#获批上市#

千呼万唤始出来！盐酸决奈达隆终于获批上市，房颤治疗迈入新时代

2022-11-07

weiz (审核中...)

前往app查看评论内容

#获批上市#

2021年12月10日简报：多数奥密克戎变异株感染病例症状轻微，中国新冠特效药中和抗体获批上市

2022-05-20

weiz (审核中...)

前往app查看评论内容

#获批上市#

国家药监局：92个医疗器械产品获批上市

2022-02-04

weiz (审核中...)

前往app查看评论内容

#获批上市#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-05-03

weiz (审核中...)

前往app查看评论内容

#获批上市#

直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！

2022-06-06

weiz (审核中...)

前往app查看评论内容

#获批上市#

君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市

2022-06-17

weiz (审核中...)

前往app查看评论内容

#获批上市#

特大喜讯！中国新冠病毒疫苗获批上市，全民免费！

2021-01-22

weiz (审核中...)

前往app查看评论内容

#获批上市#

500多万癫痫儿童用药有了新选择，优时比维派特®口服溶液获批上市

2022-01-12

weiz (审核中...)

前往app查看评论内容

#获批上市#

中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！

2021-06-29

docwu2019 (审核中...)

前往app查看评论内容

#获批上市#

韩国GC绿十字公司血友病药物绿茵芷获批上市

2022-07-02

weiz (审核中...)

前往app查看评论内容

#获批上市#

武田高血压新药「美阿沙坦钾片」在中国获批上市

2021-10-06

weiz (审核中...)

前往app查看评论内容

#获批上市#

第二个国产三代EGFR-TKI获批上市

2022-01-28

weiz (审核中...)

前往app查看评论内容

#获批上市#

两款国产疫苗同时获批上市，老年人群将全面覆盖

2021-12-26

weiz (审核中...)

前往app查看评论内容

#获批上市#

全球**抗过敏型隐形眼镜正式获批上市

2022-01-15

科室
- - 订阅+
  - 更多科室
工具
服务